ABCB5(+) stem cells for treating ocular disease
AssigneesVA Boston Healthcare System, The Schepens Eye Research Institute, Inc., Children's Medical Center Corporation
InventorsMarkus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
Life of this patent
Estimating the term…
Abstract
Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
Claims10
A method of treating a subject having an ocular condition, wherein the ocular condition is a corneal disease, comprising administering to the subject isolated ABCB5(+) ocular stem cells, wherein the ocular stem cells are limbal stem cells, in an amount effective to regenerate ocular cells in the subject.
A method of promoting ocular cell regeneration, wherein the ocular cells are corneal cells, comprising identifying limbal stem cells as ABCB5(+) limbal stem cells and administering to a subject in need thereof the ABCB5(+) limbal stem cells in an amount effective to promote corneal cell regeneration.
Dependencies are inferred from the claim text.